Adaptive Biotechnologies
ADPT
231 hedge funds and large institutions have $4.8B invested in Adaptive Biotechnologies in 2021 Q2 according to their latest regulatory filings, with 38 funds opening new positions, 99 increasing their positions, 60 reducing their positions, and 56 closing their positions.
160% more call options, than puts
Call options by funds: $20.2M | Put options by funds: $7.79M
65% more repeat investments, than reductions
Existing positions increased: 99 | Existing positions reduced: 60
1.96% more ownership
Funds ownership: 81.74% → 83.7% (+2%)
5% more capital invested
Capital invested by funds: $4.58B → $4.8B (+$215M)
7% less funds holding
Funds holding: 249 → 231 (-18)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
32% less first-time investments, than exits
New positions opened: 38 | Existing positions closed: 56
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$54.2M |
| 2 |
NAMA
Nikko Asset Management Americas
New York
|
+$53.8M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$52.2M |
| 4 |
SM
SB Management
Abu Dhabi,
United Arab Emirates
|
+$48.2M |
| 5 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$37.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$46.3M |
| 2 |
Wells Fargo
San Francisco,
California
|
-$30.4M |
| 3 |
Rockefeller Capital Management
New York
|
-$21.4M |
| 4 |
MCMC
Matrix Capital Management Company
Portsmouth,
New Hampshire
|
-$19.8M |
| 5 |
GLA
Great Lakes Advisors
Chicago,
Illinois
|
-$13.4M |
ADPT Hedge Fund Activity: Q2 2021 in Review
231 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Adaptive Biotechnologies (ADPT) for Q2 2021, worth a combined $4.8B — up 4.7% from $4.58B a quarter earlier.
Sellers outnumbered buyers: 56 funds closed out of ADPT and 38 opened new positions — a net loss of 18 holders — while 60 trimmed existing stakes and 99 added.
The largest buyer was Sumitomo Mitsui Trust Group, adding an estimated $54.2M. The largest seller was JP Morgan Chase, cutting an estimated $46.3M.
- 231 institutional investors held Adaptive Biotechnologies (ADPT) as of Q2 2021, down from 249 in Q1 2021.
- Funds reported $4.8B of Adaptive Biotechnologies stock for Q2 2021, up 4.7% quarter-over-quarter.
- 38 funds opened new Adaptive Biotechnologies positions in Q2 2021 and 56 closed out, a net change of -18 holders.
- The largest Adaptive Biotechnologies buyer in Q2 2021 was Sumitomo Mitsui Trust Group, an estimated $54.2M added.
- The largest Adaptive Biotechnologies seller in Q2 2021 was JP Morgan Chase, an estimated $46.3M sold.
Based on aggregated 13F filings for Q2 2021.